Skip to main content

Advertisement

SpringerLink
Log in

Adjunct Divalproex or Lithium to Clozapine in Treatment-Resistant Schizophrenia

  • Published:
Psychiatric Quarterly Aims and scope Submit manuscript

Abstract

This retrospective study examined adjunct divalproex (N = 15) or lithium (N = 9) in treatment-resistant schizophrenia patients added to clozapine and compared to clozapine monotherapy (N = 25). Six month total BPRS scores were similarly improved in all treatment groups, however significantly greater improvements occurred in the first month for those on divalproex (-9) or lithium (−8) vs. clozapine alone (−4.5) (F = 3.32, df = 10.43, p = 0.0003). Rates of sedation, tachycardia, orthostasis, GI disturbances, confusion and dizziness were similar among groups. Mean weight gain was 8.7 pounds for clozapine monotherapy, 3.0 pounds in the adjunct divalproex group and 13.3 pounds in the adjunct lithium group (P = NS). A trend was noted for greater increases in blood glucose levels for those treated with adjunct lithium (F = 2.62, df = 2.28, p = 0.09). The addition of divalproex was significantly more effective in reducing global symptoms (driven by hostility and anxiety) in the first month of adjunct treatment as compared to clozapine monotherapy and to previous clozapine treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Conley RR, Kelly DL: Management of treatment-resistant schizophrenia. Biological Psychiatry 50:898–911, 2001.

    Article  CAS  PubMed  Google Scholar 

  2. Chakos M, Lieberman J, Hoffman E, et al: Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: A review and meta-analysis of randomized trials. American Journal of Psychiatry 158:518–526, 2001.

    Article  CAS  PubMed  Google Scholar 

  3. Chong S-A, Remington G: Clozapine augmentation: Safety and efficacy. Schizophrenia Bulletin 26:421–440, 2000.

    CAS  PubMed  Google Scholar 

  4. Casey DE, Daniel DG, Wassef AA, et al: Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacology 28:182–192, 2003

    Article  CAS  PubMed  Google Scholar 

  5. Afaq I, Riaz J, Sedky K, et al: Divalproex as a calmative adjunct for aggressive schizophrenic patients. Journal of the Kentucky Medical Association 100:17–22, 2002.

    PubMed  Google Scholar 

  6. Morinigo A, Martin J, Gonzalex S, et al: Treatment of resistant schizophrenia with valproate and neuroleptic drugs. Hillside Jounal of Clinical Psychiatry 11:199–207, 1989.

    CAS  Google Scholar 

  7. Dose M, Hellweg R, Yassouridis A, et al: Combined treatment of schizophrenic psychoses with haloperidol and valproate. Pharmacopsychiatry 31:122–125, 1998.

    Article  CAS  PubMed  Google Scholar 

  8. Littrell KH, Petty RG, Hilligoss NM, et al: Valproate for hostility in schizophrenia patients. Journal of Clinical Psychiatry 65:134, 2004.

    Google Scholar 

  9. Chong S-A, Tan C-H, Lee E-L, et al: Augmentation of risperidone with valproic acid. Journal of Clinical Psychiatry 59:430, 1998.

    Google Scholar 

  10. Wassef AA, Dott SG, Harris A, et al: Randomized placebo-controlled pilot study of divalproex sodium in the treatment of acute exacerbations of chronic schizophrenia. Journal of Clinical Psychopharmacology 20:357–361, 2000.

    Article  CAS  PubMed  Google Scholar 

  11. Loscher W: Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS drugs 16:669–694, 2002.

    PubMed  Google Scholar 

  12. Citrome L: Schizophrenia and valproate. Psychopharmacology Bulletin 37 suppl 2:74–88, 2003.

    Google Scholar 

  13. Stahl SM: Anticonvulsants as mood stabilizers and adjuncts to antipsychotics: valproate, lamotigine, carbamazepine, and oxcarbazepine and actions at voltage-gated sodium channels. Journal of Clinical Psychiatry 65:738–739, 2004.

    PubMed  Google Scholar 

  14. Citrome L, Levine J, Allingham B: Changes in the use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998. Psychiatric Services 51:634–638, 2000.

    Article  CAS  PubMed  Google Scholar 

  15. Bender S, Linka T, Wolstein J, et al: Safety and efficacy of combined clozapine-lithium pharmacotherapy. International Journal of Neuropsychopharmacology 7:59–63, 2004.

    CAS  PubMed  Google Scholar 

  16. Leucht S, Kissling W, McGrath J: Lithium for schizophrenia revisited: a systematic review and meta-analysis of randomized controlled trials. Journal of Clinical Psychiatry. 65(2):177–186, 2004.

    Article  CAS  PubMed  Google Scholar 

  17. Kando JC, Tohen M, Castillo J, et al: Concurrent use of clozapine and valproate in affective and psychotic disorders. Journal of Clinical Psychiatry 55:255–257, 1994.

    CAS  PubMed  Google Scholar 

  18. Bender SA, Wolstein JR, Ortmann K, et al: Treatment of schizophrenia and schizoaffective disorder with a combination of clozapine and lithium. European Neuropsychopharmacology 6:200, 1996.

    Google Scholar 

  19. Citrome L, Casey DE, Daniel DG, et al: Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone. Psychiatric Services 55:290–294, 2004.

    PubMed  Google Scholar 

  20. Stahl SM: Anticonvulsants as mood stabilizers and adjuncts to antipsychotics: valproate, lamotrigine, carbamazepine, and oxcarbamazepine and actions at voltage-gated sodium channels. Journal of Clinical Psychiatry 65:738–739, 2004.

    PubMed  Google Scholar 

  21. Kremer I, Vass A, Gorelik I, et al: Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia. Biological Psychiatry 56:441–446, 2004.

    Article  CAS  PubMed  Google Scholar 

  22. Meyer JM: A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. Journal of Clinical Psychiatry 63:425–433, 2002.

    CAS  PubMed  Google Scholar 

  23. Jafari M, Jiang P, Casey DE: Adjunctive divalproex sodium lowers cholesterol elevation with olanzapine. Presented at the American Psychiatric Association, New York, NY, May 2004

  24. Horie S and Suga T: Enhancement of perioxisomal beta-oxidation in the liver of rats and mice treated with valproic acid. Biochemical Pharmacology 4:1357–1385, 1984.

    Google Scholar 

  25. Bolanos JP, Medina JM, Williamson DH: Inhibition of sterol but fatty acid synthesis by valproate in developing rat brain in vivo. Biochemical Journal 272:251–253, 1990.

    CAS  PubMed  Google Scholar 

  26. Nikolaos T, Stylianos G, Chryssoula N, et al: The effect of long-term antiepileptic treatment on serum cholesterol (TC, HDL, LDL) and triglyceride levels in adult epileptic patients on monotherapy. Medical Science Monitor 10:50–52, 2004.

    Google Scholar 

  27. Henderson DC, Cagliero E, Gray C, et al: Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. American Journal of Psychiatry 157:975–981, 2000.

    Article  CAS  PubMed  Google Scholar 

  28. Koval MS, Rames LJ, Christie S: Diabetic ketoacidos associated with clozapine treatment. American Journal of Psychiatry 151:1520–1521, 1994.

    CAS  PubMed  Google Scholar 

  29. Peterson GA, Byrd SL: Diabetic ketoacidosis from clozapine and lithium cotreatment. American Journal of Psychiatry. 153:737–738, 1996.

    CAS  PubMed  Google Scholar 

  30. Ananth J, Johnson KM, Levander EM, et al: Diabetic ketoacidosis, neuroleptic syndrome, and myocardial infarction in a patient taking risperidone and lithium carbonate. Journal of Clinical Psychiatry 65:724, 2004.

    Google Scholar 

  31. Jones GR, Lazarus JH, Davies CJ, et al: The effect of short term lithium carbonate in Type II diabetes mellitus. Hormone Metabolism Research 15:422–424, 1983.

    Article  CAS  Google Scholar 

  32. Peterson GA, Byrd SL: Diabetic ketoacidosis from clozapine and lithium cotreatment. Amerian Journal of Psychiatry 153:727–728, 1996.

    Google Scholar 

  33. Boylan LS, Labovitz DL: Unbalanced statistical analysis of combined divalproex and antipsychotic therapy for schizophrenia. Neuropsychopharmacology 29:636, 2004.

    Google Scholar 

  34. Altamura AC, Baile R, Mauri M, et al: Valpromide (Depamide) in the treatment of acute psychotic states. Open clinical study. Acta Psychiatrica Belgium 86:297–304, 1986.

    CAS  Google Scholar 

  35. Negron AE: Divalproex sodium extended release (Depakote ER) for the acute treatment of schizophrenia: a retrospective chart review. Presented at the 44 Annual NCDEU Meeting, Phoenix, Arizona, June 1–4, 2004.

  36. Facciola G, Avenoso A, Scordo MG, et al: Small effects of valproic acid on plasma concentrations of clozapine and its major metabolites in patients with schizophrenic or affective disorders. Therapeutic Drug Monitoring 21:341–345, 1999.

    Article  CAS  PubMed  Google Scholar 

  37. Longo LP, Salzman C: Valproic acid effects on serum concentrations of clozapine and norclozapine. American Journal of Psychiatry 152:650–651, 1995.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Maryland Psychiatric Research Center, University of Maryland, Box 21247, Baltimore, MD, 21228

    Deanna L. Kelly Pharm.D., Robert R. Conley M.D., Stephanie Feldman M.S.W., Yang Yu M.A., Robert P. McMahon Ph.D. & Charles M. Richardson M.D.

Authors
  1. Deanna L. Kelly Pharm.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert R. Conley M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stephanie Feldman M.S.W.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yang Yu M.A.
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Robert P. McMahon Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Charles M. Richardson M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Deanna L. Kelly Pharm.D..

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kelly, D.L., Conley, R.R., Feldman, S. et al. Adjunct Divalproex or Lithium to Clozapine in Treatment-Resistant Schizophrenia. Psychiatr Q 77, 81–95 (2006). https://doi.org/10.1007/s11126-006-7963-9

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11126-006-7963-9

Key Words

Search

Navigation